medigraphic.com
ISSN 0188-9796 (Print)

2004, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2004; 12 (3)

Osteoporosis
Position of the Sociedad Mexicana de Nutrición y Endocrinología

Reza AAA, Vergara LA, Mendoza ZV, Martínez SC, Zúñiga GS, Porias CHL, Arechavaleta GR

Language: Spanish
References: 70
Page: 126-163
PDF size: 319.84 Kb.


Text Extraction

No abstract


REFERENCES

  1. Schurch MA, Rizzoli R, Mermillod B et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996; 11: 1935-42.

  2. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom 1998; 1: 395-402.

  3. Cumming R, Cummings S, Nevitt M et al. Calcium intake and fracture risk: results from the study of osteoporotic fractures. Am J Epidemiol 1997; 145: 927-35.

  4. Hannan MT, Tucker KL, Dawson-Hughes B et al. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000; 15: 2504-12.

  5. Heaney RP, Weaver CM. Calcium and vitamin D. Endocrinol Metab Clin N Am 2003; 32: 181-94.

  6. Heaney RP. Estrogen-calcium interactions in the postmenopause: a quantitative description. Bone Miner 1990; 11: 67-84.

  7. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both Type I and Type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Mineral Res 1998; 13: 763-73.

  8. Falahati-Nina A, Riggs BL, Atkinson EJ et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106: 1553-60.

  9. Shea B, Wells G, Cranney A et al. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocrine Reviews 2002; 23(4): 552-9.

  10. Chevalley T, Rizzoli R, Nydegger V et al. Effects on calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replet elderly patients. Osteoporosis Int 1994; 4: 245-52.

  11. Reid IR, Ames RW, Evans MC et al. Effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1993; 328: 460-64.

  12. Recker R, Hinders S, Daves M et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996; 11: 1961-6.

  13. Riggs BL, O´Fallon MW, Muhs J et al. Long term effects of calcium supplementation on serum parathyroid hormone levels, bone turnover, and bone loss in elderly women. J Bone Miner Res 1998; 13: 168-74.

  14. Hansson T, Roos B. The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. Calcif Tissue Int 1987; 40: 315-7.

  15. Davis JW, Ross PD, Johnson NE et al. Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination. Bone 1995; 17: 369-73.

  16. Nieves JW, Komar L, Cosman F et al. Calcium potentiates the effect of estrogen and calcitonin on bone mass; review and analysis. Am J Clin Nutr 1998; 67: 18-24.

  17. Honkanen RJ, Alhava E, Saarikoski S et al. Interaction of calcium and HRT in the prevention of bone loss and fractures in early postmenopausal women. J Bone Miner Res 1999; 14 (suppl 1): S181.

  18. NIH Consensus Conference. Optimal calcium intake. JAMA 1994; 272: 1942-8.

  19. Häuselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis Int 2003; 14: 2-12.

  20. The osteoporosis methodology group and the osteoporosis research advisory group. Meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 2002; 23 (4): 496-507.

  21. Heaney RP, Barger-Lux MJ, Dowell MS et al. Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab 1997; 82: 4111-6.

  22. Devine A, Wilson SG, Dick IM et al. Effects of vitamin D metabolites on intestinal calcium absorption and bone turnover in elderly women. Am J Clin Nutr 2002; 75: 283-8.

  23. Papadimitropoulos E, Wells G, Shea B et al. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrine Reviews 2002; 23 (4): 560-9.

  24. Heaney RP. Nutritional factors in osteoporosis. Annu Rev Nutr 1993; 13:287-316.

  25. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42.

  26. Dawson-Hughes B, Harris S, Krall E, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6.

  27. Peacock M, Liu G, Carey M et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000; 85: 3011-9.

  28. Wells G, Tugwell P, Shea B et al. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocrine Reviews 2002; 23 (4): 529-39.

  29. Khosla S, Bilezikian JP. The Role of estrogens in men and androgens in women. Endocrinol Metab Clin N Am 2003; 32: 195-218.

  30. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285:2891-7.

  31. Hulley S, Grady D, Furberg C et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.

  32. Herrington DM, Reboussin DM, Brosnihan B et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9.

  33. Viscoli CM, Brass LM, Kernan WN et al. A clinical trial of estrogen-replacement therapy after isquemic stroke. N Engl J Med 2001; 345: 1243-9.

  34. Wassertheil-Smoller S, Hendrix SL, Limancher L et al (WHI Investigators). Effect of estrogen plus progestin on stroke in postmenopausal women: the Women´s Health Initiative: a randomized trial. JAMA 2003; 289 (20): 2673-84.

  35. Anderson GL, Limacher M, Assaf AR et al (WHI steering committee). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women´s Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1769-71.

  36. Writing Group for the Women´s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women´s Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33.

  37. Anderson GL, Judd HL, Kaunitz AM et al (WHI Investigators). Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women´s Health Initiative randomized trial. JAMA 2003; 290(13): 1739-48.

  38. Kim C, Kwok Y. Decision analysis of hormone replacement therapy after the Women´s Health Initiative. Am J Obstet Gynecol 2003; 189: 1228-33.

  39. Cranney A, Tugwell P, Zytaruk N et al. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocrine Reviews 2002; 23 (4): 524-8.

  40. Fontana A, Delmas P. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinol Metab Clin N Am 2003; 32: 219-32.

  41. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene. JAMA 1999; 282: 637-45.

  42. Cauley JA, Norton L, Lippman LE et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breat Cancer Res Treat 2001; 65: 125-34.

  43. McClung MR. Bisphosphonate. Endocrinol Metab Clin N Am 2003; 32: 253-71.

  44. Cranney A,Wells G, Willan A et al. II Meta-analysis of alendronato for the treatment of postmenopausal women. Endocrine Reviews 2002; 23 (4): 508-16.

  45. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 2000; 12: 1-12.

  46. Ravn P, Bidstrup M, Wasnich RD et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized controlled trial. Ann Intern Med 1999; 131: 935-42.

  47. Ravn P, Weiss SR, Rodriguez-Portales JA et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000; 85: 1492-7.

  48. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-10.

  49. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids; a randomized, double-blind, placebo controlled extension trial. Arthritis Rheum 2001; 44: 202-11.

  50. Cranney A, Tugwell P, Adachi J et al. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Reviews 2002; 23(4): 517-23.

  51. Mortensen L, Charles P, Bekker PJ et al. Risedronate increases bone mass in an early postmenopausal population : two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396-402.

  52. Brown JP, Kendler DL, McClung MR et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-11.

  53. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277-85.

  54. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate : 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group. J Clin Endocrinol Metab 2000; 85: 3109-15.

  55. Silverman SL. Calcitonin. Endocrinol Metab Clin N Am 2003; 32: 273-84.

  56. Cranney A, Tugwell P, Zytaruk N et al. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocrine Reviews 2002; 23(4): 540-51.

  57. Chesnut CH, Silverman SL, Andriano K et al. Prospective, randomized trial of nasal spray calcitonin in postmenopausal women with established osteoporosis; the PROOF study. Am J Med 2000; 109: 267-76.

  58. Trovas GP, Lyritis G, Galanos A et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002; 17: 521-7.

  59. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metab Clin N Am 2003; 32: 285-307.

  60. Riggs BL, Hodgson SF, O´Fallon WM et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-9.

  61. Pak CY, Sakhaee K, Adams-Huet B et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401-8.

  62. Pak CY, Zerwekh JE, Antich PP et al. Slow-release sodium fluoride in osteoporosis. J Bone Miner Res 1996; 11: 561-4.

  63. Meunier PJ, Roux C, Seeman E et al. The effects of Strontium Ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.

  64. Fuleihan GE. Strontium Ranelate- A novel theraphy for osteoporosis or a permutation of the same. N Engl J Med 2004; 350: 504-6.

  65. Fisher W J, Cummings S R, Greenspan S. New treatments for growing scourge of brittle bones. Annals of Intern Med 2004; 140(2): 153-6.

  66. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.

  67. Deal C. The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep 2004; 6(1): 49-58.

  68. Doggrell SA. Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis? Expert Opin Pharmacother 2004; 5(4): 955-8.

  69. Horwitz MJ, Tedesco MB, Gundberg C et al. Short term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 569-75.

  70. Guyatt GH, Cranney A, Griffith MS et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin N Am 2002; 31: 659-79.




2020     |     www.medigraphic.com